文献速递瓣膜病与结构性心脏病心律失常

生物瓣主动脉瓣置换术后抗凝对瓣膜血流动力学和临床结局的影响

Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究基于PARTNER2试验及注册队列的4832例生物瓣主动脉瓣置换患者(TAVR 3889例,SAVR 943例),评估出院时抗凝对瓣膜血流动力学和临床结局的影响。结果显示抗凝未显著影响主动脉瓣平均压差或瓣口面积,但未抗凝组30天至1年平均压差增加>10 mmHg的比例更高(2.3% vs 1.1%,p=0.03);SAVR后抗凝与卒中减少独立相关(HR 0.17,95%CI 0.05-0.60,p=0.006),而TAVR后抗凝与不良结局无独立关联。

要点

  • 生物瓣AVR后早期抗凝未显著影响主动脉瓣平均压差或瓣口面积。
  • 未抗凝组30天至1年平均压差增加>10 mmHg的比例显著高于抗凝组(2.3% vs 1.1%,p=0.03)。
  • SAVR后抗凝与卒中显著减少独立相关(HR 0.17,95%CI 0.05-0.60,p=0.006),TAVR后无此关联。

核心结论

  • 生物瓣AVR后早期抗凝未导致不良临床事件,未显著影响主动脉瓣血流动力学,且与SAVR后卒中减少相关(但TAVR后无此关联)。
  • 早期抗凝对生物瓣AVR长期结局的影响尚待确定。

研究设计与样本

  • 研究汇总PARTNER2随机试验和非随机注册队列数据,共纳入4832例生物瓣主动脉瓣置换患者(TAVR 3889例,SAVR 943例)。
  • 收集抗血小板和抗血栓治疗数据,于AVR后30天和1年行超声心动图检查。
  • 采用线性回归模型评估抗凝对瓣膜血流动力学的影响,采用倾向性评分校正的Cox比例风险模型评估对临床结局的影响。

主要发现

  • 校正瓣膜尺寸、瓣环直径、心房颤动和射血分数后,TAVR或SAVR队列中出院抗凝与未抗凝患者的主动脉瓣平均压差或瓣口面积均无显著差异。
  • 未抗凝组30天至1年平均压差增加>10 mmHg的患者比例显著高于抗凝组(2.3% vs 1.1%,p=0.03)。
  • TAVR后抗凝与不良结局无独立关联(死亡,p=0.15;再住院,p=0.16)。
  • SAVR后抗凝与卒中显著减少独立相关(HR 0.17,95%CI 0.05-0.60,p=0.006)。

临床怎么用

  • 对于生物瓣SAVR术后患者,早期抗凝可能有助于降低卒中风险,但需结合个体情况权衡。
  • 对于TAVR术后患者,早期抗凝未显示独立临床获益,决策应基于其他适应证。
  • 抗凝对生物瓣血流动力学无显著不良影响,未抗凝者需关注压差增加风险。

局限性

  • 早期抗凝对生物瓣AVR长期结局的影响尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is paucity of evidence on the impact of anticoagulation (AC) after bioprosthetic aortic valve replacement (AVR) on valve hemodynamics and clinical outcomes. OBJECTIVES: The study aimed to assess the impact of AC after bioprosthetic AVR on valve hemodynamics and clinical outcomes. METHODS: Data on antiplatelet and antithrombotic therapy were collected. Echocardiograms were performed at 30 days and 1 year post-AVR. Linear regression model and propensity-score adjusted cox proportional model were used to assess the impact of AC on valve hemodynamics and clinical outcomes, respectively. RESULTS: A total of 4,832 patients undergoing bioprosthetic AVR (transcatheter aortic valve replacement [TAVR], n = 3,889 and surgical AVR [SAVR], n = 943) in the pooled cohort of PARTNER2 (Placement of Aortic Transcatheter Valves) randomized trials and nonrandomized registries were studied. Following adjustment for valve size, annular diameter, atrial fibrillation, and ejection fraction at the time of assessment of hemodynamics, there was no significant difference in aortic valve mean gradients or aortic valve areas between patients discharged on AC vs. those not discharged on AC, for either TAVR or SAVR cohorts. A significantly greater proportion of patients not discharged on AC had an increase in mean gradient >10 mm Hg from 30 days to 1 year, compared with those discharged on AC (2.3% vs. 1.1%, p = 0.03). There was no independent association between AC after TAVR and adverse outcomes (death, p = 0.15; rehospitalization, p = 0.16), whereas AC after SAVR was associated with significantly fewer strokes (hazard ratio [HR]: 0.17; 95% confidence interval [CI]: 0.05-0.60; p = 0.006). CONCLUSIONS: In the short term, early AC after bioprosthetic AVR did not result in adverse clinical events, did not significantly affect aortic valve hemodynamics (aortic valve gradients or area), and was associated with decreased rates of stroke after SAVR (but not after TAVR). Whether early AC after bioprosthetic AVR has impact on long-term outcomes remains to be determined. (Placement of AoRTic TraNscathetER Valves [PARTNERII A]; NCT01314313).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chakravarty T, Patel A, Kapadia S, et al. Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement. J Am Coll Cardiol. 2019. PMID: 31466616. doi:10.1016/j.jacc.2019.06.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。